GCM
CTIC

Graham Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Graham Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,834
Closed -$284K – 1446
2022
Q3 		$284K Buy
+48,834
New +$304K 0.01% 922

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Graham Capital Management's CTIC Position: Q4 2022 in Review

Graham Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 48,834 shares — an estimated $284K sold.

Graham Capital Management first reported a position in CTIC in Q3 2022 and held it in 1 quarter. The position peaked at $284K in Q3 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Graham Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Graham Capital Management sold 48,834 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $284K.
  • Graham Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 1 quarter.
  • Graham Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $284K in Q3 2022.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Graham Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.